A study to investigate a new drug called Efzofitimod for people with pulmonary sarcoidosis

Upcoming study
Expected to open September 2022
This study is currently recruiting
Expected to close December 2024
This study is closed
This study closed in December 2024
We will update this page with study results when available.
Information on study results are included below
This study closed in December 2024
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

A new drug, called Efzofitimod, has shown potential to help people affected by severe inflammatory lung diseases. The drug works by dampening the immune responses, in the hope that it will resolve inflammation and prevent lung scarring from occurring. Small scale studies in patients with pulmonary sarcoidosis have shown a potential beneficial effect, however, this was only in a small number of people.

This study aims to investigate further in a larger group of people, to see if the drug could help people with pulmonary sarcoidosis, and if it has less severe side effects compared to other therapies.


What is involved?

You will be assigned to one of three groups.

  • Group 1 and 2 will receive the study drug, Efzofitimod, through an intravenous infusion. This is a drip where the drug is provided directly into the bloodstream, in the form of fluids. The only difference between the two groups is the amount of drug that is given at each infusion. The infusions are every 4 weeks and there are a total of 12 doses in total.
  • Group 3 will receive a placebo. This is something that looks exactly like the drug, but there are no active drug ingredients in the infusions.

You will not know which group you have been assigned to until the end of the study.

The researchers will measure your lung function at different points in the study, take blood tests and ask you to complete questionnaires to see if there are any benefits for taking the drug.

Summary of involvement

Duration up to 49 weeks

Infusions every 4 weeks, with a total of 12 doses

Infusions will either be with the study drug or a placebo

Blood tests


Lung function tests

Can I take part?

You may be able to take part if you are aged between 18 and 75 years, and have a diagnosis of pulmonary sarcoidosis. You must have been receiving a stable dose of oral corticosteroids medication for at least 3 months. Your body weight must be between 40 and 160 kg.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the clinical trial team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Aged 18-75 years

Diagnosis of pulmonary sarcoidosis

Experiencing symptoms of disease

Stable dose of oral corticosteroids for at least 3 months

Body weight between 40 - 160 kg

You will not be able to join the study of any of the following applies:

You can't be taking more than 1 oral immunosuppressant therapy

Significant pulmonary fibrosis that has increased by more than 20% within the last 12 months

Severe pulmonary hypertension

There are other specific exclusion criteria points, but these will be explored by the research team

What difference could taking part make?

Taking part in this study will help researchers to understand if the new drug, Efzofitimod, has the potential to help people with pulmonary sarcoidosis, by reducing inflammation, symptom relief, subsequent scarring of the lung tissue, and stabilising the disease.

Taking part in research not only helps researcher now, but it helps those affected by the disease in the future. All research leads us to finding better and more effective treatment options, by figuring out what does and doesn't work.

Where does the study take place?

Study locations






You may be able to take part in the study, if you do not live close to a research site, but are prepared to travel in order to take part. This will not affect you current standard treatment that you receive.

How to take part

If you would like to take part in this study or find out more information, please speak to your healthcare team to express your interest in research. You can also visit the Efzo-fit website to find out more and see if you Pre-Qualify to take part.

Further information

The summary on this page provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.


This study is supported by

aTyr Pharma, Inc.
Kyorin Pharmaceutical Co.,Ltd
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org